CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Treace Medical Q3 revenue falls but slightly beats expectations

By Reuters News


Overview

  • US bunion surgery device maker's Q3 revenue fell 4% yr/yr, slightly beating analyst expectations

  • Adjusted EBITDA turned positive in Q3, improving from a loss a year earlier

  • Revenue decline driven by shift to lower-priced minimally invasive products and lower kit volumes


Outlook

  • Treace Medical sees 2026 revenue at $206 mln to $210 mln, down from prior $204 mln-$212 mln range

  • Treace Medical reiterates expectation for 2026 cash usage to fall about 50% from 2025


Result Drivers

  • PRODUCT MIX SHIFT - Co said revenue declined mainly due to greater sales of lower-priced minimally invasive products and lower volume of bunion procedure kits

  • INCREASED ADOPTION - Co reported higher adoption of expanded bunion portfolio, with about 45% of Lapiplasty surgeon users now using one or more new systems, up from 40% in Q2

  • EXPENSE REDUCTION - Operating expenses fell 10% yr/yr, attributed to targeted expense reduction initiatives


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$48.25 mln

$47.80 mln (5 Analysts)

Q3 Loss Per Share

$0.19

Q3 Gross Margin

79.50%

Q3 Gross Profit

$38.35 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Reuters Recommended Reads

  • Nov 5 - Apyx Medical Q3 revenue beats estimates on AYON system demand

  • Nov 5 - Globus Medical Q3 sales fall 0.7%, miss estimates; adjusted EPS beats

  • Nov 3 - RxSight Q3 revenue falls on competitive pressures


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.